top of page
IMG_6973.webp

Our Story of Aiming To Transform Intravascular Imaging

We're On a Mission To Deliver Precision and Innovation in Patient Care

01

Our Mission

At VerAvanti, our mission is to advance medical diagnostics and treatment with precise, single-use endoscopic solutions focused on patient safety, efficiency, and diagnostic accuracy. Recognizing the limitations of traditional side-view imaging and reusable scopes, we collaborated with the University of Washington to develop our patented SaFE technology. Each step has brought us closer to creating a product that meets the needs of modern healthcare.

​

As we aim for FDA approval in 2025, VerAvanti is preparing to expand production and introduce our diagnostic solutions worldwide. Committed to ongoing innovation, we aim to improve healthcare standards by making procedures safer, faster, and more effective for both patients and providers.

02

The Timeline

LongGradient.webp

1

Foundational Research and Collaboration

Laying the groundwork for groundbreaking technology.

Initial research began in collaboration with the University of Washington, forming the basis for our fiber-optic endoscopy innovations.

LongGradient.webp

2

Prototype Testing and Validation

Ensuring safety and effectiveness through testing.

Early prototypes underwent rigorous lab and clinical testing, validating our imaging excellence.

LongGradient.webp

3

Securing 50+ Patents

Protecting our technology through comprehensive patents.

We secured over 50 patents in the U.S.A, reinforcing VerAvanti’s commitment to advancing exclusive, protected innovations.

LongGradient.webp

5

Final Production Model Established

Refining the design for scalability and precision.

The production model is under finalization, with in-house manufacturing processes set up to maintain quality and precision at scale.

LongGradient.webp

6

FDA Approval and Market Launch

Bringing VerAvanti’s innovations to healthcare providers.

With FDA approval anticipated by 2025, VerAvanti is poised to launch its technology globally, redefining standards in diagnostics and treatment.

03

Leadership

VerAvanti_Top+Ortho(Gray+Background).jpg

Gerald McMorrow

Founder and CEO

With a proven track record for spotting and commercializing scanning and imaging technology that can make a difference in the lives of physicians worldwide, serial entrepreneur Gerald McMorrow is launching VerAvanti. Previously, McMorrow founded and led Verathon Inc., to soaring heights as Chief Executive Officer and Chairman, responsible for guiding the company’s transformation from start-up to a major international medical device corporation, before steering its eventual sale to Roper Industries. A recognized industry powerhouse, McMorrow was named Ernst & Young Entrepreneur of The Year (2006, Pacific Northwest, Health Services category) and leveraged his early engineering experience and career into the high reaches of corporate management. McMorrow worked his way through school with the aid of the G.I. Bill and has Bachelor's and Master's degrees cum laude in Electrical Engineering from the University of Washington, Seattle.
VerAvanti_Top+Ortho(Gray+Background).jpg

Luis Savastano

Chief Medical Officer

Dr. Savastano is a surgeon-scientist, inventor and entrepreneur dedicated to advance endovascular and minimally invasive surgery through the development of new technologies and techniques. He is a hybrid cerebrovascular neurosurgeon and currently Assistant Professor of Neurosurgery and Radiology at the Mayo Clinic, Rochester MN. In addition, he is the Principal Investigator of the Mayo's Translational Neurosurgery and Biotechnology Laboratory which is dedicated to transforming clinical challenges into opportunities for breakthrough innovations. Dr. Savastano has had leading roles in technology development spanning the translational research spectrum from device conception to commercialization. He has conducted trailblazer research on SaFE angioscopy and has pioneered its use in carotid arteries disease and stroke.
VerAvanti_Top+Ortho(Gray+Background).jpg

Eric Seibel

Chief Science Officer

Research Professor of Mechanical Engineering at the University of Washington and the Director of the Human Photonics Laboratory. Eric invented the scanning fiber endoscope (SaFE) and many of its current application.
VerAvanti_Top+Ortho(Gray+Background).jpg

Juan Vegarra

Chief Marketing Officer

An Innovative leader with a demonstrated history of successfully implementing global sales and marketing initiatives.
VerAvanti_Top+Ortho(Gray+Background).jpg

David Goesling

Chief Financial Officer

Senior financial executive with extensive startup and growth-phase experience in private and public companies; skilled in raising capital and enhancing business models to drive financial results.
VerAvanti_Top+Ortho(Gray+Background).jpg

Jason Capodanno

Chief Operating Officer

Jason Capodanno is the Managing Director of Avanti with a degree in BioEngineering from the University of California at San Diego. His background in class II and III medical devices started in 1998 with Gerald McMorrow at Diagnostic Ultrasound (later Verathon) as a Manufacturing Engineer on the very successful BVI3000 Product. He then spent 6 years as a Microfluidics Design Engineer currently holding 16 patents in that field. Next he spent a decade with Philips Medical as a Design Engineer, Procurement Engineer and Supplychain/Operations. The various disciplines of Jason’s experience and leadership fits Avanti’s needs well in building a team to take a low volume/high cost product and transforming it into a high volume/low cost one.

Clinical Advisors

VerAvanti_Top+Ortho(Gray+Background).jpg

Patrick McVeigh, MD

MD

Dr. McVeigh is with the Division of Vascular Surgery at the University of Toronto. His PhD in Medical Biophysics produced the 1st in-vivo studies of intravascular imaging using the SFE.
VerAvanti_Top+Ortho(Gray+Background).jpg

Mark Reisman

Clinical Professor of Medicine

Mark Reisman is a Clinical Professor of Medicine at the University of Washington. He is also President of the Board of Directors of the Seattle Science Foundation and the Director of several cardiology programs throughout the country. Dr. Reisman has been the site Principal Investigator on more than 50 clinical trials and remains an active investigator on a multitude of trials with a focus on structural heart disease and coronary artery disease. As Director of Cardiovascular Emerging Therapies, he has a research interest in emerging technologies for the treatment of heart disease.
VerAvanti_Top+Ortho(Gray+Background).jpg

William Lombardi

Associate Clinical Professor of Medicine

Dr. Lombardi is an associate clinical professor of medicine in the Division of Cardiology, and the director for Complex Coronary Artery Disease Therapies in the UW Medicine Regional Heart Center. He is an expert in cardiac catheterization and interventional cardiology.
VerAvanti_Top+Ortho(Gray+Background).jpg

John Petersen

Director of Cardiovascular Research

John L. Petersen is Director of Cardiovascular Research at Swedish Heart & Vascular Institute and specializes in Interventional Cardiology. He attended the University of Washington School of Medicine, and completed his residency at Duke University Medical Center. Dr. Petersen is not only a renowned Cardiologist at Swedish, he also spends his time working closely with Fellows and new research on the University of Washington campus, and is a member of the American College of Cardiology, Society for Cardiovascular Angiography and Interventions and American Heart Association.

Board Members

VerAvanti_Top+Ortho(Gray+Background).jpg

Gerald McMorrow

Chairman of the Board

With a proven track record for spotting and commercializing scanning and imaging technology that can make a difference in the lives of physicians worldwide, serial entrepreneur Gerald McMorrow is launching VerAvanti. Previously, McMorrow founded and led Verathon Inc., to soaring heights as Chief Executive Officer and Chairman, responsible for guiding the company’s transformation from start-up to a major international medical device corporation, before steering its eventual sale to Roper Industries. A recognized industry powerhouse, McMorrow was named Ernst & Young Entrepreneur of The Year (2006, Pacific Northwest, Health Services category) and leveraged his early engineering experience and career into the high reaches of corporate management. McMorrow worked his way through school with the aid of the G.I. Bill and has Bachelor's and Master's degrees cum laude in Electrical Engineering from the University of Washington, Seattle.
VerAvanti_Top+Ortho(Gray+Background).jpg

Fred Moll

M.D., Founder and CEO of Auris Health

Dr. Moll is a distinguished and prolific medical device entrepreneur. Prior to Auris, he founded three public companies, including Hansen Medical (HNSN), Restoration Robotics (HAIR), and Intuitive Surgical (ISRG). Earlier, he served as a founder and medical director of Origin Medsystems, acquired by Eli Lily, and Endotherapeutics, acquired by United States Surgical.
VerAvanti_Top+Ortho(Gray+Background).jpg

David C. Auth

Ph.D, Affiliate Professor of Bioengineering

Renowned scientist, inventor, businessman, and serial medical device pioneer. Currently serves on several medical technology company boards, and has been an Affiliate Professor of Bioengineering at the University of Washington since 1985.
VerAvanti_Top+Ortho(Gray+Background).jpg

Michael Moyer

Board Member

Mike Moyer is a corporate finance and securities attorney with almost three decades of experience serving emerging companies and the venture funds and family offices that invest in them. He is a partner at the firm of BakerHostetler where he leads the firm’s national Emerging Companies & Venture Capital group and its Seattle Business Group.  He handles public and private securities offerings, mergers and acquisitions and the formation of strategic alliances and joint ventures.
bottom of page